Renal Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Renal Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-19EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG
European Medicines Agency authorises Opdivo (nivolumab) for multiple cancer indications, including melanoma, non-small cell lung cancer, ren…
-
EMA approval · 2026-07-01EMA Authorised: Keytruda (pembrolizumab) — Merck Sharp & Dohme B.V.
EMA authorises Keytruda (pembrolizumab) for multiple cancer indications, including melanoma, Hodgkin disease, renal cell carcinoma, non-smal…
-
EMA approval · 2026-04-22EMA Authorised: Keytruda (pembrolizumab) — Merck Sharp & Dohme B.V.
The European Medicines Agency authorised Keytruda (pembrolizumab) for multiple cancer indications, including melanoma, Hodgkin lymphoma, ren…
-
EMA approval · 2026-04-09EMA Authorised: Sorafenib Accord (sorafenib tosilate) — Accord Healthcare S.L.U.
The EMA authorised Sorafenib Accord (sorafenib tosylate) for hepatocellular carcinoma and renal cell carcinoma. Accord Healthcare S.L.U. is …
-
EMA approval · 2026-03-26EMA Authorised: Kisplyx (lenvatinib mesilate) — Eisai GmbH
The European Medicines Agency authorised Kisplyx (lenvatinib mesilate) by Eisai GmbH for renal cell carcinoma. The decision included acceler…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-03-25EMA Authorised: Zirabev (bevacizumab) — Pfizer Europe MA EEIG
Zirabev (bevacizumab) has been authorised by EMA for multiple cancer indications, including colorectal, breast, non-small cell lung, renal c…
-
EMA approval · 2026-03-18EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG
EMA authorised Opdivo (nivolumab) for multiple cancer indications, including melanoma, Hodgkin lymphoma, renal cell carcinoma, non-small cel…
-
EMA approval · 2026-02-27EMA Authorised: Cabometyx (cabozantinib (s)-malate) — Ipsen Pharma
The EMA authorised Cabometyx (cabozantinib (s)-malate) for renal cell carcinoma and hepatocellular carcinoma in the EU, with Ipsen Pharma as…
-
EMA approval · 2026-02-06EMA Authorised: Alymsys (bevacizumab) — Mabxience Research SL
The EMA authorised Alymsys, a bevacizumab biosimilar from Mabxience Research SL. It is approved for multiple cancer indications including co…
-
EMA approval · 2026-02-05EMA Authorised: Avzivi (bevacizumab) — FGK Representative Service GmbH
EMA authorised Avzivi (bevacizumab) for multiple indications including colorectal cancer, non-small cell lung cancer, renal cell carcinoma, …
-
EMA approval · 2026-01-28EMA Authorised: Abevmy (bevacizumab) — Biosimilar Collaborations Ireland Limited
EMA authorised Abevmy (bevacizumab) as a biosimilar. It is approved for several cancer indications including colorectal, breast, ovarian, fa…
-
EMA approval · 2026-01-28EMA Authorised: Vegzelma (bevacizumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Vegzelma, a bevacizumab biosimilar from Celltrion Healthcare Hungary Kft., for multiple cancers including colorectal, breast,…
-
EMA approval · 2026-01-28EMA Authorised: Aybintio (bevacizumab) — Samsung Bioepis NL B.V.
The EMA authorised Aybintio, a bevacizumab biosimilar from Samsung Bioepis NL B.V., for multiple cancer indications including colorectal, br…
-
EMA approval · 2026-01-27EMA Authorised: Mvasi (bevacizumab) — Amgen Technology (Ireland) UC
EMA authorised Mvasi (bevacizumab) from Amgen as a biosimilar to bevacizumab for multiple cancer indications including renal cell carcinoma,…
-
EMA approval · 2026-01-27EMA Authorised: Avastin (bevacizumab) — Roche Registration GmbH
The EMA authorised Avastin (bevacizumab) under Roche Registration GmbH for multiple cancer indications. The listed diseases include non-smal…
-
EMA approval · 2026-01-13EMA Authorised: Welireg (belzutifan) — Merck Sharp & Dohme B.V.
The European Medicines Agency authorised Welireg (belzutifan) for renal cell carcinoma and von Hippel-Lindau disease, in the EU under condit…
-
EMA approval · 2025-12-04EMA Authorised: Sunitinib Accord (sunitinib) — Accord Healthcare S.L.U.
The European Medicines Agency authorised Sunitinib Accord for the treatment of gastrointestinal stromal tumors, renal cell carcinoma, and ne…
-
EMA approval · 2025-11-21EMA Authorised: Yervoy (Ipilimumab) — Bristol-Myers Squibb Pharma EEIG
The European Medicines Agency authorised Yervoy (ipilimumab) for multiple cancer indications. It lists melanoma, renal cell carcinoma, non-s…
-
EMA approval · 2025-11-20EMA Authorised: Afinitor (everolimus) — Novartis Europharm Limited
EMA authorised Afinitor (everolimus) for renal cell carcinoma, breast cancer and pancreatic neoplasms. The marketing authorisation holder is…
-
FDA approval · 2025-10-30FDA Approved: EVEROLIMUS — Original Application (Novugen Pharma (USA) LLC.)
FDA approved a generic version of Everolimus from Novugen Pharma (USA) LLC under an Original Application (ANDA).
-
EMA approval · 2025-10-28EMA Authorised: Votrient (pazopanib) — Novartis Europharm Limited
The EMA authorised pazopanib (Votrient) for renal cell carcinoma in the European Union. The Marketing Authorization Holder is Novartis Europ…
-
EMA approval · 2025-09-11EMA Authorised: Axitinib Accord (axitinib) — Accord Healthcare S.L.U.
The EMA authorised a new marketing authorisation for axitinib under the brand Axitinib Accord by Accord Healthcare S.L.U. for renal cell car…
-
FDA approval · 2025-09-04FDA Approved: PAZOPANIB — Original Application (Torrent Pharmaceuticals Limited)
FDA approves Torrent Pharmaceuticals Limited's pazopanib hydrochloride as an original generic application (ANDA 219922).
-
EMA approval · 2025-03-28EMA Authorised: Nexavar (sorafenib) — Bayer AG
The EMA authorised Nexavar (sorafenib) for hepatocellular carcinoma and renal cell carcinoma. The decision date was 13 February 2025.
-
EMA approval · 2025-03-10EMA Authorised: Sutent (sunitinib) — Pfizer Limited
Sutent (sunitinib) has been authorised by the EMA with indications for gastrointestinal stromal tumor, renal cell carcinoma, and neuroendocr…